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Abstract 
Review on cutaneous mastocytosis, with data on 
clinics, pathology, and involved genes. 
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Clinics and pathology 
Disease 
Cutaneous mastocytosis is characterized as a 
proliferation of mast cells in the skin.  Three main 
forms of cutaneous mastocytosis are recognized: 
urticaria pigmentosa/maculopapular cutaneous 
mastocytosis (MPCM), mastocytoma, and diffuse 
cutaneous mastocytosis (DCM) (Hartmann et al, 
2016).  MPCM is subdivided into 2 variants: a 
monomorphic variant and a polymorphic variant 
(Hartmann et al, 2016). Of note, systemic 
mastocytosis can also have cutaneous involvement. 
Phenotype/cell stem origin 
The cells of origin are mast cells. 
Epidemiology 
Cutaneous mastocytosis is predominantly a disease 
of childhood. In a literature review involving 1747 
cases, 23% of cases had congenital mastocytosis and 
90% of cases had disease onset before the 2 years of 
age (Méni et al, 2015).  In a series of 101 children 
with mastocytosis, 73% of cases presented within the 
first 6 months of life and 97% of cases presented by 
2 years of age (Lange et al, 2013) Urticaria 
pigmentosa/maculopapular cutaneous mastocytosis 
(MPCM) has the highest incidence rate of 74.8-
84.7%, followed by mastocytoma at 6.9-19.5%, and 
lastly diffuse cutaneous mastocytosis at 5.2-9% 
(Bodemer et al, 2010; Lange et al, 2013; Kiszewski 
et al, 2004; Méni et al, 2015; Wiechers et al, 2015). 
Polymorphic MPCM is more prevalent in children 
with an earlier onset (< 7 months of age) and shorter 
duration of disease (Wiechers et al, 2015). 
Monomorphic MPCM usually has a later onset of 
disease (58% of children have onset of disease after 
24 months of age) and increased disease duration 
with persistence into adulthood (Wiechers et al, 
2015).  In this respect, monomorphic MPCM has 
been postulated to represent an early presentation of 
systemic mastocytosis.  Approximately 4-8% of 
patients with cutaneous mastocytosis have familial 
disease (Bodemer et al, 2010; Méni et al, 2015). 
Adults usually present with either MCPM or DCM, 
not cutaneous mastocytomas (Hartmann et al, 2016). 
Clinics 
In any of the subtypes of cutaneous mastocytosis, 
blistering and/or bullae may occur.  Between 40-
100% of cases demonstrate Darier's sign, in which a 
wheal and flare is elicited after slight scratching (Le 
et al, 2017).  However, it is recommended not to 
perform Darier sign in cases of DCM and large 
mastocytomas as it could lead to massive mast cell 
degranulation with severe symptoms (Matito et al, 
2018; Klaiber et al, 2017).  Other skin manifestations 
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include pruritus and flushing.  Most of the symptoms 
including the gastrointestinal complaints, such as 
pain and vomiting, are due to release of mediators 
from the mast cells.  Symptoms appear to be more 
frequent in patients with DCM (Méni et al, 2015).  
Maculopapular cutaneous mastocytosis (MPCM) 
lesions have variable appearances, including 
reddish-brown macules, papules, plaques, or small 
nodules.  Those with monomorphic maculopapular 
lesions usually have lesions measuring  
Cutaneous mastocytoma usually presents as a single 
elevated red-brown or orange-yellow nodule 
measuring >1 cm in diameter.  The term 
mastocytoma can also be used when there are up to 
three lesions as long as they are morphologically 
different than typical MPCM (Hartmann et al, 2016). 
Mastocytomas are predominantly on the extremities 
but also can occur on the head and trunk (Hartmann 
et al, 2016).  These lesions usually blister.  
Diffuse cutaneous mastocytosis (DCM) usually 
presents as diffusely erythematous and thickened 
skin (pachydermia), sometimes with a peau d'orange 
(orange peel) or leathery appearance. However, 
papules may also be present. These children often 
demonstrate dermographism, in which a wheal and 
flare response occurs after scratching in surrounding 
normal skin.  Blistering is also very common.  Cases 
of DCM usually present prior to 7 months of age.   
While they can have elevated serum tryptase levels, 
this elevation is believed to be more related to the 
marked mast cell infiltrate of the skin and not due to 
systemic involvement (Carter et al, 2015; Wiechers 
et al, 2015). 
Pathology 
In all three types of cutaneous mastocytosis, mast 
cells infiltrate the dermis, sparing the epidermis.  
These mast cells are often spherical or spindled in 
shape with round to oval nuclei, clumped chromatin, 
inconspicuous nucleoli, and plentiful cytoplasm 
filled with tiny granules.   
Mast cells should be increased at least 4-8 fold 
compared to normal skin for a diagnosis. In urticaria 
pigmentosa/maculopapular cutaneous mastocytosis, 
the mast cells are prominent in the papillary dermis 
and extend into the reticular dermis in a periadnexal 
and perivascular distribution.  Admixed eosinophils 
may be present.  The overlying epidermis may be 
hyperpigmented.  In mastocytoma, the skin shows 
sheets of mast cells in the full thickness dermis, 
sometimes infiltrating into the subcutaneous adipose 
tissue.  In diffuse cutaneous mastocytosis, the skin 
has a band-like mast cell infiltrate in the papillary 
and superficial reticular dermis; the overlying 
epidermis may be hyperpigmented. 
 
Figure 1: Urticaria pigmentosa/maculopapular cutaneous mastocytosis.  A) Hematoxylin and eosin (HE, 100X) demonstrating a 
proliferation of mast cells surrounding vessels and adnexa within the dermis.  B) Higher power (HE, 400X) shows mast cells with 
round to elongate nuclear contours, and moderate amounts of lightly basophilic cytoplasm.  C) Toluidine blue stain highlights the 
mast cell granules in a blue/purple color (400X).  D) Giemsa staining highlights the mast cell granules in purple (400X). 
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Figure 2: Cutaneous mastocytoma.  A) Hematoxylin and eosin (HE, 40X) demonstrating a diffuse proliferation of mast cells 
spanning the dermis.  B) Higher power (HE, 100X) shows the proliferation of mast cells in the papillary dermis between rete 
pegs.  C) High power (HE, 400X) demonstrating the mast cells with round nuclear contours and moderate to ample amounts of 




In pediatric cutaneous mastocytosis, somatic 
mutations in KIT are identified in up to 86% of cases 
of skin biopsies (Bodemer et al, 2010).  Most 
commonly (in approximately 34-42% of cases), 
these mutations involve the kinase domain, in exon 
17, and specifically at amino acid 816 (Bodemer et 
al, 2010; Méni et al, 2015). This mutation is usually 
p.D816V, but also rarely p.D816Y and p.D816I.  
Another 44% of mutations are identified in exons 8 
and 9, involving the fifth Ig loop of the extracellular 
domain, as well as exon 11 (Bodemer et al, 2010).  
Mutations in these other exons are mutually 
exclusive of mutations at codon 816. No specific 
genotype-phenotype correlations have been 
identified (Bodemer et al, 2010).  The mutations 
cause constitutive ligand-independent activation of 
KIT (Bodemer et al, 2010).  KIT D817V mutations 
are usually not identified in peripheral blood in those 
with only cutaneous disease, but can be found in 
those with systemic disease (Carter et al, 2018).  
There is no identified association between clinical 
subtype and the identified KIT mutation (Meni et al, 
2018). 
Treatment 
Therapies for cutaneous mastocytosis are usually 
based upon symptoms.  Most commonly 
antihistamines are used, especially in urticarial 
pigmentosa.  However, the efficiency of 
antihistamines varies from complete resolution to no 
resolution of symptoms such as pruritus (Le et al, 
2017).  Topical corticosteroids can be used in 
cutaneous mastocytoma cases, usually resulting in 
complete resolution and plaque regression (Le et al, 
2017). Oral corticosteroids can lead to rapid 
regression and remission of blistering in bullous 
cutaneous lesions of diffuse cutaneous mastocytosis 
(Le et al, 2017).  Phototherapy can also be used to 
decrease refractory pruritus in urticarial pigmentosa 
and decrease dermographism and leathery skin 
thickening in diffuse cutaneous mastocytosis (Le et 
al, 2017). Imatinib and omalizumab can be used in 
cutaneous mastocytoses, with the former decreasing 
pruritus and bullous lesions, and the latter preventing 
bronchospasm and anaphylaxis (Le et al, 2017). 
Evolution 
Many cases of mastocytosis resolve over a period 
years, usually puberty.  These lesions may start as 
nodules during infancy, transform into plaques in 
mid childhood, and then into macules after 10 years 
of age, before regressing during puberty (Hartmann 
et al, 2016).  In some that don't regress completely, 
the lesions may flatten with time (Hartmann et al, 
2016).  Blistering usually lessens within 3-4 years of 
lesion identification (Hartmann et al, 2016). In a 
large literature review with outcome data on 621 
cases with a median follow-up of 6 years, complete 
regression was observed in 29% of cases, partial 
regression in 39% of cases, and stabilization in 27% 
of cases (Méni et al, 2015).  In another large 
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literature review, mastocytomas had a complete 
resolution rate of 10% per year and urticarial 
pigmentosa had a resolution rate of 1.9% per year; 
diffuse cutaneous mastocytosis did not show 
evidence of complete resolution (Le et al, 2017).  Of 
note, in children with monomorphic MPCM, the 
lesions may persist into adulthood and represent 
systemic mastocytosis (Hartmann et al, 2016; 
Wiechers et al, 2015).  There is no identified 
association between evolution of the skin lesions and 
the identified KIT mutation (Meni et al, 2018). 
Prognosis 
In children, the prognosis is favorable, with most 
patients showing some degree of spontaneous 
regression by puberty (Hartmann et al, 2016). Of 
note, cutaneous mastocytosis in children is usually 
not a systemic disease and routine bone marrow 
evaluations are not recommended, unless signs of 
systemic mastocytosis are present such as 
hepatosplenomegaly (Carter et al, 2015).  However, 
in adults, cutaneous mastocytosis more commonly is 
associated with systemic mastocytosis. 
Genes involved and 
proteins 




Mutations cause constitutive ligand-independent 
activation of KIT, with the highest phosphorylation 
status for exon 17 mutations. 
DNA/RNA 21 exons 
Protein 
This protein is a transmembrane receptor for mast 
cell growth factor (also known as stem cell factor) 
which has tyrosine kinase activity. 
Somatic mutations 
34-42% of cases have mutations at D816 in exon 17 
(usually p.D816V, but also rarely p.D816Y and 
p.D816I (Bodemer et al, 2010)).  Other mutations 
occur in the fifth Ig loop of the extracellular domain 
encoded by exon 8 (InsFF419, Δ 419, Δ 417-
419insY, Δ 418-419insS, C443Y), exon 9 (S476I, 
ITD501-502, ITD502-503, Δ 503-504insSY 
ITD505-508, Δ Δ508-509insYFAF, K509I), and 
exon 11 (Δ 564-576, D572A) (Bodemer et al, 2010, 
Meni et al, 2018). 
References 
Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-
Guyodo C, Leventhal PS, Hadj-Rabia S, Nasca L,  
Georgin-Lavialle S, Cohen-Akenine A, Launay JM, Barete 
S, Feger F, Arock M, Catteau B, Sans B, Stalder JF, 
Skowron F, Thomas L, Lorette G, Plantin P, Bordigoni P, 
Lortholary O, de Prost Y, Moussy A, Sobol H, Dubreuil P. 
Pediatric mastocytosis is a clonal disease associated with 
D816V and other activating c-KIT mutations. J Invest 
Dermatol. 2010 Mar;130(3):804-15 
Carter MC, Bai Y, Ruiz-Esteves KN, Scott LM, Cantave D, 
Bolan H, Eisch R, Sun X, Hahn J, Maric I, Metcalfe DD. 
Detection of KIT D816V in peripheral blood of children 
with manifestations of cutaneous mastocytosis suggests 
systemic disease. Br J Haematol. 2018 Dec;183(5):775-782 
Carter MC, Clayton ST, Komarow HD, Brittain EH, Scott LM, 
Cantave D, Gaskins DM, Maric I, Metcalfe DD. Assessment 
of clinical findings, tryptase levels, and bone marrow 
histopathology in the management of pediatric 
mastocytosis. J Allergy Clin Immunol. 2015 
Dec;136(6):1673-1679.e3 
Hartmann K, Escribano L, Grattan C, et al. Cutaneous 
manifestations in patients with mastocytosis: Consensus 
report of the European Competence Network on 
Mastocytosis; the American Academy of Allergy, Asthma & 
Immunology; and the European Academy of Allergology 
and Clinical Immunology. J Allergy Clin Immunol. 2016 
Jan;137(1):35-45 
Kiszewski AE, Durán-Mckinster C, Orozco-Covarrubias L, 
Gutiérrez-Castrellón P, Ruiz-Maldonado R. Cutaneous 
mastocytosis in children: a clinical analysis of 71 cases J 
Eur Acad Dermatol Venereol  2004 May;18(3):285-90 
Klaiber N, Kumar S, Irani AM. Mastocytosis in Children Curr 
Allergy Asthma Rep  2017 Oct 7;17(11):80 
Lange M, Niedoszytko M, Renke J, Gle&nacute; J, 
Nedoszytko B. Clinical aspects of paediatric mastocytosis: 
a review of 101 cases J Eur Acad Dermatol Venereol  2013 
Jan;27(1):97-102 
Le M, Miedzybrodzki B, Olynych T, Chapdelaine H, Ben-
Shoshan M. Natural history and treatment of cutaneous and 
systemic mastocytosis Postgrad Med  2017  
Nov;129(8):896-901 
Méni C, Bruneau J, Georgin-Lavialle S, Le Saché de 
Peufeilhoux L, Damaj G, Hadj-Rabia S, Fraitag S, Dubreuil 
P, Hermine O, Bodemer C. Paediatric mastocytosis: a 
systematic review of 1747 cases Br J Dermatol  2015 
Mar;172(3):642-51 
Matito A, Azaña JM, Torrelo A, Alvarez-Twose I. Cutaneous 
Mastocytosis in Adults and Children: New Classification and 
Prognostic Factors Immunol Allergy Clin North Am  2018 
Aug;38(3):351-363 
Meni C, Georgin-Lavialle S, Le Saché de Peufeilhoux L, 
Jais JP, Hadj-Rabia S,  Bruneau J, Fraitag S, Hanssens K, 
Dubreuil P, Hermine O, Bodemer C. Paediatric 
mastocytosis: long-term follow-up of 53 patients with whole 
sequencing of KIT A  prospective study  Br J Dermatol 
Wiechers T, Rabenhorst A, Schick T, Preussner LM, Förster 
A, Valent P, Horny HP, Sotlar K, Hartmann K. Large 
maculopapular cutaneous lesions are associated with 
favorable outcome in childhood-onset mastocytosis J 
Allergy Clin Immunol  2015 Dec;136(6):1581-1590 
This article should be referenced as such: 
Chisholm KM. Cutaneous mastocytosis. Atlas Genet 
Cytogenet Oncol Haematol. 2020; 24(2):83-86. 
